| 0 (0%) | 09-27 09:34 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.64 | 1-year : | 0.75 |
| Resists | First : | 0.55 | Second : | 0.64 |
| Pivot price | 0.54  |
|||
| Supports | First : | 0.53 |
Second : | 0.52 |
| MAs | MA(5) : | 0.54 |
MA(20) : | 0.54 |
| MA(100) : | 0.74  |
MA(250) : | 2.42 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 99.1 |
D(3) : | 97.6 |
| RSI | RSI(14): 70.4 | |||
| 52-week | High : | 10.5 | Low : | 0.22 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ MRNS ] has closed below upper band by 16.3%. Bollinger Bands are 97.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.55 - 0.55 | 0.55 - 0.56 |
| Low: | 0.54 - 0.55 | 0.55 - 0.55 |
| Close: | 0.54 - 0.55 | 0.55 - 0.56 |
Sat, 27 Sep 2025
MARINUS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Wed, 25 Jun 2025
Attention Hauliers: £2,500 Civil Penalty for Non-Compliance from 7th April 2025 - East Lancashire Chamber of Commerce
Tue, 11 Feb 2025
Marinus Pharmaceuticals CEO Scott Braunstein sells $167,530 in stock - Investing.com
Tue, 11 Feb 2025
Immedica Pharma Completes Acquisition of Marinus Pharmaceuticals - TipRanks
Fri, 10 Jan 2025
Marinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Mon, 30 Dec 2024
Silicon Valley - FinancialContent
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 3.739e+007 (%) |
| Held by Institutions | 10.9 (%) |
| Shares Short | 3,220 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.2866e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -376 % |
| Return on Assets (ttm) | -57.8 % |
| Return on Equity (ttm) | -2 % |
| Qtrly Rev. Growth | 3.026e+007 % |
| Gross Profit (p.s.) | 25.79 |
| Sales Per Share | 782.97 |
| EBITDA (p.s.) | -5.33016e+007 |
| Qtrly Earnings Growth | -2.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -120 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 2.23 |
| Dividend | 0 |
| Forward Dividend | 5.66e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|